% | $
Quotes you view appear here for quick access.

Halozyme Therapeutics, Inc. Message Board

  • fezziwig2008 fezziwig2008 Oct 22, 2013 9:40 AM Flag

    Folfoirinox Added 4 mos to Gem- Pegph20 Added 6 mos * to Folfirinox- The Combo May Cure High Hyal Patients

    Fol-Peg Represents an Exciting Fully Owned Halozyme Rx in Ph2 Clinical Trials With Hope of FDA Breakthrough Status and Expeditied Review
    Phase 4b Panc Ca Surv- Gem alone- 7 mos, Fol- alone 11 mos, Gem-PegpH20- 17+ mos*
    * in High Hyaluron Tumors

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • SO, The 2 agents with the longest survival rates in History for Pancreatic CA 4b Join Forces, wholly owned by Halozyme- nice

    • Yes, this is very exciting news!

      I am surprised given how deadly pancreatic cancer is, the estimated primary completion date is December 2017 (4 years from start date) and the Estimated Study Completion Date: May 2019. Maybe with good results they approve it earlier.

      Estimated Enrollment: 172
      Study Start Date: December 2013
      Estimated Study Completion Date: May 2019
      Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)

    • afriendofthedevilsafriendofmine afriendofthedevilsafriendofmine Oct 22, 2013 9:53 AM Flag


      I doubt Pegph20 would be partnered for use with Gemcitabine or Abraxane or both at only 5% of revenue. It is a stand alone drug capable of Breaking open some solid tumors and suppressing mets (if the data bears out) and should command the same premium regardless of whether it is used with generics or chemo drugs under patent. I believe the folfirinox trial has only to do with latest SOC.


9.18+0.12(+1.32%)10:43 AMEDT